REGENERON PHARMACEUTICALS (RGO.DE) Stock Price & Overview
FRA:RGO • US75886F1075
Current stock price
The current stock price of RGO.DE is 633.8 EUR. Today RGO.DE is down by -0.98%. In the past month the price decreased by -4.83%.
RGO.DE Key Statistics
- Market Cap
- 67.005B
- P/E
- 16.80
- Fwd P/E
- 15.91
- EPS (TTM)
- 37.72
- Dividend Yield
- 0.50%
RGO.DE Stock Performance
RGO.DE Stock Chart
RGO.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RGO.DE.
RGO.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to RGO.DE. Both the health and profitability get an excellent rating, making RGO.DE a very profitable company, without any liquidiy or solvency issues.
RGO.DE Earnings
On January 30, 2026 RGO.DE reported an EPS of 11.44 and a revenue of 3.88B. The company beat EPS expectations (5.66% surprise) and beat revenue expectations (0.21% surprise).
RGO.DE Forecast & Estimates
38 analysts have analysed RGO.DE and the average price target is 746.96 EUR. This implies a price increase of 17.85% is expected in the next year compared to the current price of 633.8.
For the next year, analysts expect an EPS growth of 5.64% and a revenue growth 11.11% for RGO.DE
RGO.DE Groups
Sector & Classification
RGO.DE Financial Highlights
Over the last trailing twelve months RGO.DE reported a non-GAAP Earnings per Share(EPS) of 37.72. The EPS decreased by -2.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.41% | ||
| ROA | 11.11% | ||
| ROE | 14.41% | ||
| Debt/Equity | 0.09 |
RGO.DE Ownership
RGO.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 29.39 | 42.737B | ||
| ARGX | ARGENX SE | 29.42 | 42.687B | ||
| 22UA | BIONTECH SE-ADR | N/A | 23.644B | ||
| ABVX | ABIVAX SA | N/A | 7.77B | ||
| 2X1 | ABIVAX SA | N/A | 7.751B | ||
| GXE | GALAPAGOS NV | N/A | 1.641B | ||
| GLPG | GALAPAGOS NV | N/A | 1.626B | ||
| NANO | NANOBIOTIX | N/A | 1.275B | ||
| PHARM | PHARMING GROUP NV | 47.89 | 1.029B | ||
| PHGN | PHARMING GROUP NV | 45.9 | 1.028B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 997.606M | ||
| 6IV | INVENTIVA SA | N/A | 990.777M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 954.74M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About RGO.DE
Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Company Info
IPO: 1991-04-02
REGENERON PHARMACEUTICALS
777 Old Saw Mill River Road
Tarrytown NEW YORK US
Employees: 15410
Phone: 17813705000
REGENERON PHARMACEUTICALS / RGO.DE FAQ
Can you describe the business of REGENERON PHARMACEUTICALS?
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
What is the stock price of REGENERON PHARMACEUTICALS today?
The current stock price of RGO.DE is 633.8 EUR. The price decreased by -0.98% in the last trading session.
Does RGO stock pay dividends?
REGENERON PHARMACEUTICALS (RGO.DE) has a dividend yield of 0.5%. The yearly dividend amount is currently 2.92.
What is the ChartMill technical and fundamental rating of RGO stock?
RGO.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the Price/Earnings (PE) ratio of REGENERON PHARMACEUTICALS (RGO.DE)?
The PE ratio for REGENERON PHARMACEUTICALS (RGO.DE) is 16.8. This is based on the reported non-GAAP earnings per share of 37.72 and the current share price of 633.8 EUR.
Is REGENERON PHARMACEUTICALS (RGO.DE) expected to grow?
The Revenue of REGENERON PHARMACEUTICALS (RGO.DE) is expected to grow by 11.11% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does REGENERON PHARMACEUTICALS (RGO.DE) report earnings?
REGENERON PHARMACEUTICALS (RGO.DE) will report earnings on 2026-04-29.